These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21470099)

  • 21. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria.
    Zanetti S; Sechi LA; Molicotti P; Cannas S; Bua A; Deriu A; Carta A; Paglietti G
    Int J Antimicrob Agents; 2005 Feb; 25(2):179-81. PubMed ID: 15664491
    [No Abstract]   [Full Text] [Related]  

  • 22. Graph Theoretical Analysis, In Silico Modeling, Synthesis, Anti-Microbial and Anti-TB Evaluation of Novel Quinoxaline Derivatives.
    Saravanan G; Selvam TP; Alagarsamy V; Kunjiappan S; Joshi SD; Indhumathy M; Kumar PD
    Drug Res (Stuttg); 2018 May; 68(5):250-262. PubMed ID: 29065435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An appraisal on synthetic and pharmaceutical perspectives of quinoxaline 1,4-di-N-oxide scaffold.
    Agrawal N; Bhardwaj A
    Chem Biol Drug Des; 2022 Sep; 100(3):346-363. PubMed ID: 35610776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
    Wang T; Tang Y; Yang Y; An Q; Sang Z; Yang T; Liu P; Zhang T; Deng Y; Luo Y
    Bioorg Med Chem Lett; 2018 Jun; 28(11):2084-2090. PubMed ID: 29748048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents.
    Torres E; Moreno E; Ancizu S; Barea C; Galiano S; Aldana I; Monge A; Pérez-Silanes S
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3699-703. PubMed ID: 21570839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones.
    Ramalingam P; Ganapaty S; Rao ChB
    Bioorg Med Chem Lett; 2010 Jan; 20(1):406-8. PubMed ID: 19962890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: In silico ADMET, antiplasmodial and antileishmanial activity.
    Quiliano M; Pabón A; Ramirez-Calderon G; Barea C; Deharo E; Galiano S; Aldana I
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1820-1825. PubMed ID: 28291694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides.
    Ortega MA; Sainz Y; Montoya ME; López De Ceráin A; Monge A
    Pharmazie; 1999 Jan; 54(1):24-5. PubMed ID: 9987794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents.
    Jaso A; Zarranz B; Aldana I; Monge A
    J Med Chem; 2005 Mar; 48(6):2019-25. PubMed ID: 15771444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical study of new TB drugs and drug combinations in mouse models.
    Nikonenko BV; Sacksteder KA; Hundert S; Einck L; Nacy CA
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):102-16. PubMed ID: 18673123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives.
    Puratchikody A; Natarajan R; Jayapal M; Doble M
    Chem Biol Drug Des; 2011 Dec; 78(6):988-98. PubMed ID: 21951363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
    Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
    J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of quinoxaline and quinoxaline 1,4-di-N-oxides derivatives as potential antiparasitic agents.
    Soto-Sánchez J; Ospina-Villa JD
    Chem Biol Drug Des; 2021 Oct; 98(4):683-699. PubMed ID: 34289242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
    Gatadi S; Gour J; Shukla M; Kaul G; Dasgupta A; Madhavi YV; Chopra S; Nanduri S
    Eur J Med Chem; 2019 Aug; 175():287-308. PubMed ID: 31096152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
    Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
    J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinoxaline 1,4-di-
    Palos I; González-González A; Paz-González AD; Espinoza-Hicks JC; Bandyopadhyay D; Paniagua-Castro N; Galeana-Salazar MS; Castañeda-Sánchez JI; Luna-Herrera J; Rivera G
    Molecules; 2024 Sep; 29(19):. PubMed ID: 39407582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.